Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Hong Kong Democratic Party Disbands After Member Vote Amid Security Crackdown 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Belarus Pledges to Halt Smuggling Balloons Into Lithuania 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Israeli Airstrike in Gaza Targets Senior Hamas Commander Amid Ceasefire Tensions 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
U.S. Soldiers Killed in ISIS Attack in Palmyra, Syria During Counterterrorism Mission 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
